March 27, 2018 / 2:44 PM / 23 days ago

BRIEF-Merck Receives Fast-Track Designation For Tepotinib In Non-Small Cell Lung Cancer In Japan

Reuters Staff

1 Min Read

March 27 (Reuters) - Merck KGaA:

* MERCK RECEIVES FAST-TRACK DESIGNATION FOR TEPOTINIB IN NON-SMALL CELL LUNG CANCER IN JAPAN

* MERCK KGAA - SAKIGAKE DESIGNATION ENCOMPASSES POSSIBILITY FOR A TARGET REVIEW PERIOD OF 6 MONTHS

* MERCK KGAA - JAPANESE MINISTRY OF HEALTH, LABOUR AND WELFARE GRANTS SAKIGAKE DESIGNATION FOR TEPOTINIB Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.

0 : 0

narrow-browser-and-phone
medium-browser-and-portrait-tablet
landscape-tablet
medium-wide-browser
wide-browser-and-larger
medium-browser-and-landscape-tablet
medium-wide-browser-and-larger
above-phone
portrait-tablet-and-above
above-portrait-tablet
landscape-tablet-and-above
landscape-tablet-and-medium-wide-browser
portrait-tablet-and-below
landscape-tablet-and-below

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.